Malcolm Lloyd-Smith Net Worth

The estimated Net Worth of Malcolm Lloyd Smith is at least $14.1 Milión dollars as of 6 February 2023. Mr. Smith owns over 15,318 units of Neurocrine Biosciences stock worth over $5,142,675 and over the last 10 years he sold NBIX stock worth over $8,985,374. In addition, he makes $0 as Chief Regulatory Officer at Neurocrine Biosciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Smith NBIX stock SEC Form 4 insiders trading

Malcolm has made over 25 trades of the Neurocrine Biosciences stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 15,318 units of NBIX stock worth $1,572,240 on 6 February 2023.

The largest trade he's ever made was selling 29,984 units of Neurocrine Biosciences stock on 7 February 2020 worth over $3,133,928. On average, Malcolm trades about 7,890 units every 84 days since 2014. As of 6 February 2023 he still owns at least 42,337 units of Neurocrine Biosciences stock.

You can see the complete history of Mr. Smith stock trades at the bottom of the page.

Malcolm Lloyd-Smith biography

Malcolm C. Lloyd-Smith serves as Chief Regulatory Officer of the Company. He was appointed Chief Regulatory Officer in September 2014 and is responsible for regulatory affairs and quality assurance. Prior to joining Neurocrine Biosciences, Mr. Lloyd-Smith served at Cadence Pharmaceuticals, Inc. as Senior Vice President, Regulatory Affairs, Quality and Clinical from August 2012 to September 2014, and previously as Senior Vice President, Regulatory Affairs and Quality Assurance from August 2008. Mr. Lloyd-Smith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc. from September 2003 to August 2008, after having served in the United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr. Lloyd-Smith served in various positions of increasing responsibility with DuPont Pharmaceuticals in Germany, Switzerland, USA and UK. Mr. Lloyd-Smith holds a B.Sc. in Pharmacology from the University of Leeds and a M.Sc. in Pharmacological Biochemistry from Hatfield Polytechnic.

How old is Malcolm Smith?

Malcolm Smith is 64, he's been the Chief Regulatory Officer of Neurocrine Biosciences since 2014. There are 3 older and 21 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.

What's Malcolm Smith's mailing address?

Malcolm's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.

Insiders trading at Neurocrine Biosciences

Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.

What does Neurocrine Biosciences do?

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders

Complete history of Mr. Smith stock trades at Neurocrine Biosciences

Neurocrine Biosciences executives and stock owners

Neurocrine Biosciences executives and other stock owners filed with the SEC include:

• Kevin Gorman,
  Chief Executive Officer, Director
• Matthew Abernethy,
  Chief Financial Officer
• Eric Benevich,
  Chief Commercial Officer
• Eiry Roberts,
  Chief Medical Officer
• Haig Bozigian,
  Chief Development Officer
• Kyle Gano,
  Chief Business Development and Strategy Officer
• Dimitri Grigoriadis,
  Chief Research Officer
• Dr. Kevin C. Gorman Ph.D.,
  CEO & Director
• Dr. Eiry Wyn Roberts,
  Chief Medical Officer
• Leslie Norwalk,
  Independent Director
• Matthew C. Abernethy,
  Chief Financial Officer
• Eric S. Benevich,
  Chief Commercial Officer
• Kyle W. Gano,
  Chief Bus. Devel. and Strategy Officer
• William Rastetter,
  Independent Chairman of the Board
• Stephen Sherwin,
  Independent Director
• Richard Pops,
  Independent Director
• George Morrow,
  Independent Director
• Gary Lyons,
  Independent Director
• Todd Tushla,
  Investor Relations
• Julie Cooke,
  Chief Human Resource Officer
• Shalini Sharp,
  Independent Director
• Darin Lippoldt,
  Chief Legal Officer and Corporate Secretary
• Malcolm Lloyd-Smith,
  Chief Regulatory Officer
• David Boyer,
  Chief Corporate Affairs Officer
• Julie S. Cooke,
  Chief HR Officer
• Darin M. Lippoldt,
  Chief Legal Officer & Corp. Sec.
• Jane Sorensen,
  Head of Investor Relations
• Dr. Jude Onyia Ph.D.,
  Chief Scientific Officer
• Dr. Dimitri E. Grigoriadis,
  Chief Research Officer
• Matt Abernethy,
  Chief Financial Officer
• Corinne H Nevinny,
  Director
• Christopher Flint O Brien,
  Sr. VP & Chief Medical Officer
• Joseph A Mollica,
  Director
• David Alexandre C Gros,
  President & COO
• Alfred Sandrock,
  Director
• Christine A Poon,
  Director
• Wylie W Vale,
  Director
• Timothy Coughlin,
  VP and Chief Financial Officer
• Jensen Margaret E Valeur,
  Senior VP and General Counsel
• Partners L P/Ilbiotechnolog...,
  
• Johanna Mercier,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Henry Pan,
  Executive VP and CMO
• Wendall Wierenga,
  EVP, Research & Development
• Richard J Ranieri,
  Sr. VP, Human Resources
• Thomas Mitchell W,
  Director
• Ingrid Delaet,
  Chief Regulatory Officer
• Paul W Hawran,
  Executive VP and CFO
• Paul J Conlon,
  Vice President Research (Biol)
• Lawrence Steinman,
  Director
• John Saunders,
  Vice President Research (Chem)
• Robert J Little,
  SVP, Commercial Operations
• D Bruce Campbell,
  Senior Vice President
• Jude Onyia,
  Chief Scientific Officer